●
Earnings Feed
Filings
Companies
Insiders
Pricing
Blog
⌘
K
Login
Start Free
$OLMA
|
10-Q
Aug 11, 4:15 PM ET
Olema Pharmaceuticals, Inc. 10-Q
Loading document...
Contents
59
Item 1. Financial Statements.
Liquidity
At-The-Market Offering
Private Placement
Warrant Exchanges
Impact of Geopolitical and Macroeconomic Events
Basis of Presentation and Consolidation
Unaudited Interim Financial Information
Use of Estimates
Cash and Cash Equivalents
Marketable Securities
Concentration of Credit Risk and Other Risks and Uncertainties
Leases
Research and Development Costs
Research Contract Costs and Accruals
Internal-Use Software
Comprehensive Loss
Stock-Based Compensation
Foreign Currency Transactions
Pre-funded Warrants
Net Loss Per Common Share
Segment Reporting
Recent Accounting Pronouncements Not Yet Adopted
Stock Option Valuation
Stock Option Activity
2020 Employee Stock Purchase Plan
Stock-Based Compensation Expense
Net Loss Per Common Share
2024 Clinical Trial Collaboration and Supply Agreement with Novartis
2020 Clinical Collaboration and Supply Agreement with Novartis
Clinical Trial Agreement with Pfizer
License Agreement with Aurigene
Management Services Agreements
Contingencies
Indemnification Agreements
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Research and development
General and administrative
Comparison of the three months ended June 30, 2025 and 2024
Research and development expenses
General and administrative expenses
Other income
Comparison of the six months ended June 30, 2025 and 2024
Research and development expenses
General and administrative expenses
Other income
Sources of liquidity
Future funding and material cash requirements
Cash flows
Operating activities
Investing Activities
Item 4. Controls and Procedures.
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosures.
Item 5. Other Information.
Item 6. Exhibits.